United States — Food and Drug Administration & Moderna

United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) is the regulatory body responsible for approving the mFlusiva vaccine. Its advisory committee's unanimous recommendation is a crucial step towards the vaccine's market entry, despite internal disputes and leadership vacancies.

Moderna: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body with whom Moderna will discuss the next randomized stage of development for SRD-002, making its involvement crucial for the therapy's future.

Moderna: Moderna is the clinical-stage biotechnology company developing the gene therapy SRD-002 for heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The positive DMC recommendation for its MUSIC-HFpEF trial and the ongoing MUSIC-HFrEF trial are significant milestones for the company, supporting its continued advancement in cardiovascular gene therapy.